PartnershipJul 23, 2026, 10:55 AM
Jyong Biotech Focuses on Global Licensing for BPH Drug
AI Summary
Jyong Biotech Ltd. reaffirmed its strategic focus on pursuing global licensing partnerships to address the growing medical needs in the urology sector, particularly for Benign Prostatic Hyperplasia (BPH). The company is actively engaging in discussions with international pharmaceutical companies, leveraging its botanical drug platform. The global BPH market is projected to grow from $13 billion in 2025 to $22-22.6 billion by 2035, with significant unmet needs due to side effects of existing treatments. Jyong Biotech has conducted four Phase III clinical trials for its BPH new drug candidate, Botreso® (API-1).
Key Highlights
- Jyong Biotech reaffirms strategic focus on global licensing partnerships for urology.
- Actively engaging in discussions with international pharmaceutical companies.
- First Taiwanese company to advance oral botanical new drug to U.S. FDA Phase III.
- Global BPH patient population reached 112.5 million in 2021, projected to 150-156 million by 2035.
- Global BPH treatment market estimated at $13 billion in 2025, expected to grow to $22-22.6 billion by 2035.
- Existing BPH treatments have 60-90% discontinuation rates due to severe side effects.
- Conducted four Phase III clinical trials for Botreso® (API-1) in Taiwan and the US.
Price Impact
More from MENS